Peptide LibraryLinaclotide dosage in published studies and labels
These are the doses used for Linaclotide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Linaclotide has FDA-approved human dosages. Linzess for adults with IBS with constipation is 290 mcg by mouth once daily; for adult chronic idiopathic constipation it is 145 mcg once daily, or 72 mcg based on presentation or tolerability. For children it is 145 mcg once daily for IBS with constipation from age 7, and 72 mcg once daily for functional constipation from age 2.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 72–290 mcg once daily, by indication and age |
| Route | Oral |
| Frequency | Once daily, on an empty stomach at least 30 minutes before a meal |
| Duration studied | Continuous |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Linzess, IBS with constipationFDA-approved label · FDA prescribing information | Adults; children aged 7 years and older | 290 mcg (adults); 145 mcg (children 7 and older) | Oral | Once daily | — | Treatment of IBS with constipation | LINZESS (linaclotide) capsules — FDA prescribing information, DailyMed |
| FDA label — Linzess, chronic idiopathic constipationFDA-approved label · FDA prescribing information | Adults with chronic idiopathic constipation | 145 mcg, or 72 mcg based on presentation or tolerability | Oral | Once daily | — | Treatment of chronic idiopathic constipation | LINZESS (linaclotide) capsules — FDA prescribing information, DailyMed |
| FDA label — Linzess, functional constipation in childrenFDA-approved label · FDA prescribing information | Children aged 2 years and older with functional constipation | 72 mcg | Oral | Once daily | — | Treatment of functional constipation | LINZESS (linaclotide) capsules — FDA prescribing information, DailyMed |
Where sources disagree
- Linzess carries a boxed warning about serious dehydration in children: it is contraindicated under 2 years of age after deaths from dehydration in neonatal mice.
- Doses depend on the condition and age; 290 mcg applies only to adults with IBS with constipation.